Lattice Biologics Ltd., a biotech company, develops, manufactures, and markets biologic allograft products for use in the field of cellular therapies and tissue engineering with a focus on bone, skin, and cartilage regeneration worldwide.
Imperfect balance sheet with weak fundamentals.
Share Price & News
How has Lattice Biologics's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: LBL's share price has been volatile over the past 3 months.
7 Day Return
1 Year Return
Return vs Industry: LBL exceeded the Canadian Biotechs industry which returned -29.3% over the past year.
Return vs Market: LBL underperformed the Canadian Market which returned 4.7% over the past year.
Price Volatility Vs. Market
How volatile is Lattice Biologics's share price compared to the market and industry in the last 5 years?
Simply Wall St News
3 weeks ago | Simply Wall StShould You Be Concerned About Lattice Biologics Ltd.'s (CVE:LBL) Historical Volatility?
2 months ago | Simply Wall StIntroducing Lattice Biologics (CVE:LBL), The Stock That Zoomed 150% In The Last Year
4 months ago | Simply Wall StDoes Lattice Biologics Ltd. (CVE:LBL) Have A High Beta?
Is Lattice Biologics undervalued compared to its fair value and its price relative to the market?
Share Price vs. Fair Value
Below Fair Value: LBL (CA$0.02) is trading above our estimate of fair value (CA$0)
Significantly Below Fair Value: LBL is trading above our estimate of fair value.
Price To Earnings Ratio
PE vs Industry: LBL is unprofitable, so we can't compare its PE Ratio to the Biotechs industry average.
PE vs Market: LBL is unprofitable, so we can't compare its PE Ratio to the Canadian market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate LBL's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: LBL has negative assets, so we can't compare its PB Ratio to the CA Biotechs industry average.
How is Lattice Biologics forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?
Forecasted Pharmaceuticals & Biotech industry annual growth in earnings
In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Lattice Biologics has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.
- Take a look at our analysis of LBL’s management and see if the CEO’s compensation is within a reasonable range, who is on the board and if insiders have been trading lately.
- Lattice Biologics competitive advantages and company strategy can generally be found in its financial reports archived here.
- Explore growth companies in the Pharmaceuticals & Biotech industry.
How has Lattice Biologics performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: LBL is currently unprofitable.
Growing Profit Margin: LBL is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: LBL is unprofitable, but has reduced losses over the past 5 years at a rate of 41.6% per year.
Accelerating Growth: Unable to compare LBL's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: LBL is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (66.2%).
Return on Equity
High ROE: LBL's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.
Return on Assets
Return on Capital Employed
How is Lattice Biologics's financial position?
Financial Position Analysis
Short Term Liabilities: LBL has negative shareholder equity, which is a more serious situation than short term assets not covering short term liabilities.
Long Term Liabilities: LBL has negative shareholder equity, which is a more serious situation than short term assets not covering long term liabilities.
Debt to Equity History and Analysis
Debt Level: LBL has negative shareholder equity, which is a more serious situation than a high debt level.
Reducing Debt: LBL's has negative shareholder equity, so we do not need to check if its debt has reduced over time.
Inventory Level: LBL has a high level of physical assets or inventory.
Debt Coverage by Assets: LBL has negative shareholder equity (liabilities exceed assets) therefore debt is not covered by short term assets.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: Whilst unprofitable LBL has sufficient cash runway for more than 3 years if it maintains its current positive free cash flow level.
Forecast Cash Runway: LBL is unprofitable but has sufficient cash runway for more than 3 years, due to free cash flow being positive and growing by 63.7% per year.
What is Lattice Biologics's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Current dividend yield vs market & industry
Notable Dividend: Unable to evaluate LBL's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.
High Dividend: Unable to evaluate LBL's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if LBL's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if LBL's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of LBL's dividend in 3 years as they are not forecast to pay a notable one for the Canadian market.
How experienced are the management team and are they aligned to shareholders interests?
Average board tenure
Guy Cook (54yo)
Mr. Guy S. Cook has been the Chief Executive Officer of Lattice Biologics Ltd. since December 23, 2013 and also serves as its President. Mr. Cook served as the Chief Executive Officer and Director of Black ...
CEO Compensation Analysis
Compensation vs Market: Guy's total compensation ($USD0.00) is below average for companies of similar size in the Canadian market ($USD154.65K).
Compensation vs Earnings: Guy's compensation has increased whilst the company is unprofitable.
|CEO, President & Director||6.2yrs||US$381.50k||no data|
|Director||26.1yrs||no data||no data|
|Director||2.7yrs||no data||no data|
|Independent Director||4.2yrs||no data||no data|
|Chair of the Scientific Advisory Board||2.7yrs||no data||no data|
Experienced Board: LBL's board of directors are considered experienced (4.2 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Lattice Biologics Ltd.'s company bio, employee growth, exchange listings and data sources
- Name: Lattice Biologics Ltd.
- Ticker: LBL
- Exchange: TSXV
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Market Cap: CA$1.869m
- Shares outstanding: 93.46m
- Website: https://www.latticebiologics.com
- Lattice Biologics Ltd.
- 512 East Madison Avenue
- Suite 101
- United States
|Ticker||Exchange||Primary Security||Security Type||Country||Currency||Listed on|
|LBL||TSXV (TSX Venture Exchange)||Yes||Voting Common Shares||CA||CAD||Dec 2015|
|B5G2||DB (Deutsche Boerse AG)||Yes||Voting Common Shares||DE||EUR||Dec 2015|
|LBLT.F||OTCPK (Pink Sheets LLC)||Yes||Voting Common Shares||US||USD||Dec 2015|
Lattice Biologics Ltd., a biotech company, develops, manufactures, and markets biologic allograft products for use in the field of cellular therapies and tissue engineering with a focus on bone, skin, and cartilage regeneration worldwide. The company offers AmnioBoost, an allograft amniotic fluid visco supplement for the treatment of joint pain associated with osteoarthritis, as well as traditional, spinal, particulate, soft tissue, dental, membrane and barrier, and demineralized bone matrix allografts. Its products are used in a range of applications, including enhancing fusion in spine surgery and breast reconstruction post mastectomy, promotion of bone regeneration in foot and ankle surgery, promotion of skull healing following neurosurgery, enhancing wound repair in burn victims, and subchondral bone defect repair in knee and other joint surgeries, as well as sports medicine indications, such as anterior cruciate ligament repair. The company is headquartered in Belgrade, Montana.
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2020/02/23 00:20|
|End of Day Share Price||2020/02/21 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.